Post-COVID Interstitial Lung Disease Management

Diagnostic Evaluation

The American Thoracic Society recommends performing baseline symptom assessment focusing on cough and dyspnea on exertion, which are key symptoms of post-COVID ILD 2
Conduct thorough lung auscultation to detect fine crackles ("velcro" crackles), which have moderate sensitivity for early ILD identification 3
High-Resolution CT (HRCT) scan is the gold standard for diagnosing ILD, which can detect ground-glass opacities, reticulation, traction bronchiectasis, and honeycombing characteristic of post-COVID ILD 4
Complete pulmonary function tests (PFTs) including FVC, TLC, and DLCO measurements to establish baseline lung function 1, 2
Consider 6-minute walk test (6MWT) to evaluate exercise capacity and detect exercise-induced oxygen desaturation 5

Implement a multidisciplinary team (MDT) approach involving pulmonologists, radiologists, and when appropriate, rheumatologists for comprehensive evaluation 3, 6
The MDT should integrate HRCT findings, PFT results, and clinical symptoms to determine disease severity and treatment approach 3
MDT collaboration increases the level of care and is especially beneficial in complex cases 3

Schedule short-term PFTs within 3 months of initial evaluation to determine rate of progression 7
Consider repeat HRCT within 6 months of initial evaluation to assess for radiological progression 7
Monitor for progressive pulmonary fibrosis (PPF), defined by: worsening respiratory symptoms, physiological evidence of progression on PFTs, and/or radiological evidence of progression on chest CT 3
For mild post-COVID ILD (FVC ≥70% and <20% fibrosis extent on HRCT), schedule PFTs every 6 months for the first 1-2 years 7
For moderate-to-severe ILD or progressive disease, increase PFT frequency to every 3-6 months 7
Consider follow-up HRCT scan 2-3 years after baseline scan for stable patients, with earlier follow-up (12 months) for concerning cases 8, 9

Consider anti-fibrotic therapy (such as nintedanib) for patients showing evidence of progressive pulmonary fibrosis despite initial management 7
Evaluate the balance between inflammatory and fibrotic ILD processes to guide treatment decisions between anti-inflammatory and anti-fibrotic approaches 7
For patients with underlying connective tissue disease contributing to post-COVID ILD, follow disease-specific treatment protocols as recommended by multidisciplinary consensus 5, 7

Do not rely solely on symptom assessment, as it lacks sensitivity for detecting ILD - 90% of patients with confirmed ILD on HRCT may not report dyspnea or cough 3
Avoid unnecessary invasive procedures such as lung biopsy for initial diagnosis - HRCT is typically sufficient for diagnosis in the post-COVID setting 7